Research Topics
Species | Christian PeschelSummaryAffiliation: Klinikum rechts der Isar Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose useWolfgang A Weber
Nuklearmedizinische Klinik, Klinikum rechts der Isar, Ismaning Strabetae 22, 81675 Munchen, Germany
J Clin Oncol 21:2651-7. 2003..To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)...
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Birgit Luber
Institut für allgemeine Pathologie und pathologische Anatomie, Technische Universitat Munchen, Trogerstraße 18, 81675 Munchen, Germany
BMC Cancer 11:509. 2011....- Myc suppression of Nfkb2 accelerates lymphomagenesisUlrich Keller
III Medical Department, Technische Universitat Munchen, Munich, Germany
BMC Cancer 10:348. 2010..The Rel/NF-kappaB family member NFKB2 is altered by chromosomal translocations or deletions in lymphoid malignancies and deletion of the C-terminal ankyrin domain of NF-kappaB2 augments lymphocyte proliferation... - Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancerChristian Peschel
Technische Universitat, III Medizinische Klinik, Munchen, Germany
Lung Cancer 60:374-80. 2008..v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC)... - Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxinsThomas Decker
III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Blood 103:2718-26. 2004..HA22 was more active than BL22. In conclusion, these immunotoxins induce caspase-mediated apoptosis involving mitochondrial damage. Combination with chemotherapy is expected to improve the efficacy of immunotoxin treatment... - Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic targetThomas Decker
IIIrd Department of Medicine, Technical University of Munich, Ismaninger Strasse 15, 81675 Munich, Germany
Br J Haematol 125:141-8. 2004..We conclude that further evaluation of cyclin E and p27 in peripheral blood cells might help to identify prognostic subgroups. In addition, inhibition of Cyclin E-cdk2 activity by Roscovitine might be a new therapeutic strategy in B-CLL... - Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cellsChristian Bogner
IIIrd Department of Medicine, Technical University of Munich, Ismaningerstrasse 15, 81675, Munich, Germany
Ann Hematol 85:458-62. 2006.... - [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]Harald Gündel
Institut und Poliklinik für Psychosomatische Medizin, Psychotherapie und Medizinische Psychologie, TU Munchen, Klinikum rechts der Isar, Langerstr 3, 81675 Munchen, Germany
Z Psychosom Med Psychother 49:246-61. 2003..We prospectively evaluated the effects of a six-session psychoeducational intervention held by medical doctors or psychologists in a German acute cancer center setting... - Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivinThomas Decker
3rd Department of Medicine, Technical University of Munich, Germany
Blood 101:278-85. 2003..We conclude from our study that rapamycin might be an attractive substance for therapy for B-CLL patients by inducing a G(1) arrest in proliferating tumor cells... 
Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptorsThomas Decker
Third Department of Medicine, Technical University of Munich, Munich, Germany
Ann Hematol 89:1125-32. 2010..IL-2 might be an important survival factor in activated B-CLL cells and might contribute to disease progression by upregulation of several critical antiapoptotic proteins...- Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expressionChristian Bogner
IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
Br J Haematol 148:99-109. 2010..Our results were confirmed in freshly isolated MCL-cells from patients with leukaemic MCL. We conclude that Bcl-2 expression is important for mediating resistance against the immunotoxin BL22 in MCL cells... - [Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]Florian Lordick
III Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU Munchen
Med Klin (Munich) 97:449-54. 2002..To identify the target group for a structured educational group intervention in an acute cancer care setting, and to prove its effectiveness... - Card9 controls a non-TLR signalling pathway for innate anti-fungal immunityOlaf Gross
III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
Nature 442:651-6. 2006..Thus, our results define a novel innate immune pathway and indicate that evolutionarily distinct ITAM receptors in innate and adaptive immune cells use diverse adaptor proteins to engage selectively the conserved Bcl10-Malt1 module... - Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine productionOlaf Gross
III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Blood 112:2421-8. 2008.... - Novel markers of mesenchymal stem cells defined by genome-wide gene expression analysis of stromal cells from different sourcesNikolas Kaltz
3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
Exp Cell Res 316:2609-17. 2010..Our observations may facilitate the study of lineage relationships in MSC as well as facilitate the development of more homogeneous cell populations for mesenchymal cell therapy... - Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18Natasha B Leighl
National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
J Clin Oncol 23:2831-9. 2005..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs... - Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinomaKathrin Abbrederis
Third Department of Medicine (Hematology/Oncology, Institute for Medical Statistics and Epidemiology, and Munich Center for Clinical Studies, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Ann Thorac Surg 82:293-7. 2006..There were no erythropoietin-related adverse events. CONCLUSIONS: Treatment with erythropoietin is effective and well tolerated in patients with esophagogastric adenocarcinoma who experience anemia during neoadjuvant chemotherapy... - Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancerJean-Yves Douillard
Centre Rene Gauducheau, Nantes, France
Lung Cancer 46:361-8. 2004..As planned, patient accrual continued to further investigate the effect of BMS-275291 on overall and progression-free survival in a phase III setting... - Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancerVerena Voelter
Centre Hospitalier Universitaire Vaudois, Multidisciplinary Oncology Center, Lausanne, Switzerland
Ann Thorac Surg 78:1037-41. 2004..Patients who are treated with neoadjuvant chemotherapy with a curative intent are exposed to toxicity that may negatively affect their future outcome... - Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximabKathrin Wanner
IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
Br J Haematol 134:475-84. 2006..mTOR inhibition is a promising therapeutic strategy in DLBCL by inducing a G1 arrest and augments rituximab-induced cytotoxicity. Therefore, combination of these drugs might be an interesting new therapeutic approach in DLBCL patients... - Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathwaysChristian Bogner
IIIrd Department of Medicine, Technical University of Munich, Munich, Germany
Exp Hematol 31:218-25. 2003..CONCLUSION: Proteasome inhibition is highly effective in proliferating B-CLL cells and induces apoptosis using a caspase-dependent and -independent pathway... - Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotidesThomas Decker
3rd Department of Medicine, Technical University of Munich, Munich, Germany
Blood 99:1320-6. 2002..In summary, immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a recombinant immunotoxin by modulation of its target. This new treatment strategy deserves further attention... - Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cellsChristian Bogner
Third Department of Medicine, Technical University of Munich, Munich, Germany
Br J Haematol 122:260-8. 2003..fmk. Lactacystin was also effective in inducing apoptosis in lymphoma cells from MCL patients. We conclude that inhibition of the proteasome might be a promising therapeutic approach for this incurable disease... - Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machineryIngo Ringshausen
Comprehensive Cancer Center, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94115, USA
Curr Drug Targets 7:1349-59. 2006..Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas... - Isolation and expansion of tumor-reactive cytotoxic T-cell clones for adoptive immunotherapyHelga Bernhard
Department of Hematology/Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Methods Mol Med 109:175-84. 2005..Tumor-reactive T-cells retain the functional activity in terms of cytolysis after expansion, encouraging their use in the immunotherapy of cancer patients... - Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging proceduresBurkhard Schmidt
Department of Hematology and Oncology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Strasse 22, 81675 Munich, Germany
Leuk Lymphoma 47:1857-62. 2006..Due to the lower false negative rate, trephine BM biopsy remains crucial for the detection of BM involvement in FL... - Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selectionPhilipp J Jost
Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
J Immunol 178:953-60. 2007..Thus, while TCR signaling to NF-kappaB controls the activation of mature T cells, we suggest that this pathway is not involved in the positive or negative selection of thymocytes... - Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigensJulia Neudorfer
Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
J Immunol Methods 320:119-31. 2007.... - Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine productionStefanie Klemm
Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
Proc Natl Acad Sci U S A 104:134-8. 2007..Thus, our results identify a NF-kappaB-inducing signaling pathway downstream of GPCRs and reveal previously unrecognized functions for Bcl10/Malt1 signaling in nonimmune cells... - Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1Florian Bassermann
Department of Internal Medicine III, Technical University of Munich, 81675 Munich, Germany, and Department of Pathology, St Jude Chidren s Research Hospital, Memphis, TN 38105, USA
J Biol Chem 282:15965-72. 2007..Thus, cyclin B1/Cdk1 may contribute to the regulation of its own abundance in early mitosis... - The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigensFlorian Scheich
Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Blood 110:2556-60. 2007..These results encourage the development of immunotherapeutic approaches against Bcr-Abl-regulated antigens for the treatment of CML patients with residual disease following therapy with Bcr-Abl kinase inhibitors... - GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatmentChristian Meyer Zum Buschenfelde
III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Cancer Res 68:5414-22. 2008..These data show the importance of membrane microdomains in the effect of rituximab and may offer a predictive factor for the responsiveness of lymphoma cells to rituximab... - Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDGAmbros J Beer
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
J Nucl Med 49:22-9. 2008..We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using (18)F-galacto-RGD and (18)F-FDG provides complementary information in cancer patients... - Induction chemotherapy in Barrett cancer: influence on surgical risk and outcomeJoerg R Siewert
Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Ann Surg 246:624-8; discussion 628-31. 2007..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer... - Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cellsKatharina S Götze
Haematologica 92:1282-3. 2007..The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy... - Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphomaKen Herrmann
Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
Clin Cancer Res 13:3552-8. 2007.... - MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunitUta Ferch
Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, 81675 Munich, Germany
Nat Immunol 8:984-91. 2007..Our results provide mechanistic insights into B cell receptor-induced survival and proliferation signals and demonstrate the selective control of c-Rel in the canonical NF-kappaB pathway... - Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilizationHelge Menzel
III Medical Department, Technical University Munich, Munich, Germany
Leuk Lymphoma 49:1337-44. 2008..The addition of rituximab to IEV salvage chemotherapy increases the response rates in B-cell NHL without affecting stem cell mobilization, but overall survival for patients proceeding to high-dose chemotherapy is not improved... - CD133-enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expressionKatharina S Götze
3rd Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
Exp Hematol 35:1408-14. 2007..In conclusion, we demonstrate that CD133-enriched Lin(-)CD34(-) cord blood cells acquire CD34 prior to cell division and that long-term hematopoietic activity is associated exclusively with expression of CD34... - PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trialFlorian Lordick
Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
Lancet Oncol 8:797-805. 2007..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis... - Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapyMarkus Schwaiger
Nuklearmedizinische Klinik und Poliklinik, , Ismaninger Str. 22, 81675, Munich, Germany
Eur J Nucl Med Mol Imaging 33:1-5. 2006 - The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulationStefanie Klemm
Third Medical Department, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
J Exp Med 203:337-47. 2006..Thus, Bcl10 and Malt1 are essential positive mediators of FcepsilonRI-dependent mast cell activation that selectively uncouple NF-kappaB-induced proinflammatory cytokine production from degranulation and leukotriene synthesis... - Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitroKristina Fleischer
Department of Hematology/Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaningerstrasse 22, D-81675 Munich, Germany
J Immunol 172:162-9. 2004.... - Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitorsNikolas von Bubnoff
Department of Internal Medicine III, Technical University of Munich, Trogerstrasse 32, D-81675 Munich, Germany
Cancer Res 63:6395-404. 2003.... - Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cellsChristian Herder
Institute for Transfusion Medicine and Immunohematology, , Sandhofstr. 1, 60528 Frankfurt am Main, Germany
Arterioscler Thromb Vasc Biol 23:2266-72. 2003.... - Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathwayFlorian Bassermann
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675, Germany
J Biol Chem 277:12437-45. 2002.... - Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)Tao Ouyang
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675 Munich, Germany
J Biol Chem 278:30028-36. 2003..These results implicate an antiapoptotic role for NIPA in NPM-ALK-mediated signaling events... - Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptorRebekka Grundler
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Germany
Blood 102:646-51. 2003..These results suggest that it may be useful to determine the exact kind of FLT3 mutation when applying receptor kinase inhibitors in clinical trials... - Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase CdeltaIngo Ringshausen
Third Department of Medicine, Technical University of Munich, Germany
Blood 100:3741-8. 2002..We conclude that activated PI-3K might be important in the pathogenesis of B-CLL, and survival signals might be mediated via PKCdelta. Therefore, inhibition of PI-3K or PKCdelta may be an innovative approach to treat B-CLL... - Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphomaKlemens Scheidhauer
Klinik und Poliklinik fur Nuklearmedizin, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
Eur J Nucl Med Mol Imaging 29:1276-82. 2002..The therapeutic activities of (131)I-labelled rituximab required to deliver similar doses should be lower than those of its murine counterpart... - Restoration of transgene expression in hematopoietic cells with drug-selectable marker genesThomas Licht
Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich Medical Center, Munich, Germany
Curr Gene Ther 2:227-34. 2002..With the use of bicistronic vectors, expression and function of therapeutic genes have been increased in tissue culture and in animal models. Further preclinical investigations are needed to identify optimal conditions for selection... - Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domainThomas Jahn
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Germany
Oncogene 21:4508-20. 2002.... - Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers
Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
Blood 99:3530-9. 2002..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs... - Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?Verena Völter
J Clin Oncol 22:573; author reply 574-5. 2004 - A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitorNikolas von Bubnoff
Department of Internal Medicine III, Technical University of Munich, D-81675 Munich, Germany
Blood 105:1652-9. 2005..Thus, this robust and simple screening system provides a rational basis for combinatorial and sequential treatment strategies in targeted cancer therapy... - Antibody-based targeted therapy for gastric cancerFlorian Lordick
Gastric Cancer 8:206-8. 2005 - Mitotic entry: a matter of oscillating destructionFlorian Bassermann
Department of Internal Medicine III, Technical University of Munich, Munich, Germany
Cell Cycle 4:1515-7. 2005..Thus, oscillating ubiquitination of nuclear cyclin B1 driven by the SCFNIPA complex contributes to the timing of mitotic entry in the mammalian cell cycle... - Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cellsSusanne Hipp
Haematologica 90:1433-4. 2005..The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient... - NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entryFlorian Bassermann
Department of Internal Medicine III, Technical University of Munich, 81675 Munich, Germany
Cell 122:45-57. 2005..Thus, SCF(NIPA)-based ubiquitination may regulate S-phase completion and mitotic entry in the mammalian cell cycle... - Long-term maintenance of hematopoietic stem cells does not require contact with embryo-derived stromal cells in coculturesRobert A J Oostendorp
Department of Cell Biology and Genetics, Erasmus University, Rotterdam, Netherlands
Stem Cells 23:842-51. 2005..In summary, we show for the first time long-term maintenance of adult bone marrow HSCs in stroma noncontact cultures and identify some secreted molecules that may be involved in this support... - Radiotherapy and chemotherapy for myoepithelioma of the sellar regionCarsten Nieder
Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
Strahlenther Onkol 181:260-3. 2005..Myoepithelioma might arise in the head and neck area, especially within the salivary glands. It is very uncommon as a primary intracranial tumor... - Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarctionIlka Ott
I.Department of Medicine, Technical University Munich, Munich, Germany
FASEB J 19:992-4. 2005..Therefore, in vitro expanded EPC-derived endothelial cells may be beneficial in the treatment of ischemic disease... - A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatmentNikolas von Bubnoff
Department of Internal Medicine III, Technical University of Munich, Munich, Germany
Cell Cycle 4:400-6. 2005..We here provide a detailed methodological description, and discuss the implications of this strategy for different clinically relevant oncogenic tyrosine kinases... - Phosphorylation of grb10 regulates its interaction with 14-3-3Susanne Urschel
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, 81675 Munich, Germany
J Biol Chem 280:16987-93. 2005..Based on these findings, we propose a regulatory circuitry involving a phosphorylation-regulated complex formation of Grb10 with 14-3-3 and Akt... - Response to chemotherapy and treating institution predict survival in primary central nervous system lymphomaAgnieszka Korfel
Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Br J Haematol 128:177-83. 2005..2 vs. 9.9 months, P = 0.02). Median survival was significantly longer at institutions accruing at least four patients than at those with fewer patients (31.5 vs. 9.5 months, P = 0.03)... - Peripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case reportRalph Czekalla
Second Department of Medicine, Bogenhausen Academic Teaching Hospital, Munich, Germany
Eur J Gastroenterol Hepatol 16:1391-400. 2004..Because of the tumour's intense expression of CD117 (c-kit), the patient is now treated with the tyrosine kinase inhibitor imatinib (STI571)... - Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cellsChristian Meyer Zum Büschenfelde
Department of Hematology Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaningerstrasse 22, D 81675 Munich, Germany
Cancer Res 62:2244-7. 2002..The potentially synergistic activity of HER2-specific antibody and CTL encourages the development of an HER2-targeted immunotherapy using a combination of inhibitory antibodies and CTLs for patients with HER2-overexpressing tumors...